Xenon Pharmaceuticals Inc (FRA:XP0)
€ 52.5 -0.50 (-0.94%) Market Cap: 5.38 Bil Enterprise Value: 4.18 Bil PE Ratio: 0 PB Ratio: 4.37 GF Score: 25/100

Xenon Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 19, 2026 / 01:30PM GMT
Brian Abrahams
RBC Capital Markets Inc - Managing Director

Hi, again, everyone. I'm Brian Abrams, Senior Biotech Analyst here at RBC Capital Markets. We're really pleased to have our next featured company, Xenon Pharmaceuticals, represented by their President and CEO, Ian Mortimer, and their CFO, Tucker Kelly. Ian and Tucker, thank you guys so much for being here.

Ian Mortimer
Xenon Pharmaceuticals Inc - President, Chief Executive Officer, Interim Chief Financial Officer, Director

Thanks, Brian. Thank you.

Questions & Answers

Brian Abrahams
RBC Capital Markets Inc - Managing Director

All right. So, it's been a really exciting year so far for you guys with some of the data we've seen from Azetukalner and the X-TOLE2 at the Phase 3 focal onset epilepsy study. And the data that you released in March demonstrated a very impressive efficacy at 43% placebo-adjusted seizure reduction at the highest dose. You got to 7% of patients to complete remission.

What's been the reactions that you guys have

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot